Senseonics Holdings, Inc. (SENS) Stock
SENS Key Statistics
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
CEO: Timothy T. Goodnow. Company website
SENS — Frequently Asked Questions
What is the SENS stock price today?
Senseonics Holdings, Inc. (SENS) trades at $10.42, up 3.89% on the day, as of Nov 12, 2026 10:46 UTC.
What is Senseonics Holdings, Inc.'s market cap?
Senseonics Holdings, Inc. has a market capitalisation of $550.95M, calculated from the live SENS share price and shares outstanding.
What is the P/E ratio of SENS?
SENS has no meaningful price-to-earnings ratio: Senseonics Holdings, Inc. lost $2.30 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Senseonics Holdings, Inc. make?
Senseonics Holdings, Inc. generated revenue of $60.01M over the trailing twelve months, which puts the stock at 9.18 times sales.
What is the 52-week range for SENS?
SENS has traded between $4.79 and $13.98 over the past 52 weeks, and the last price is 25.5% below that high.
Is Senseonics Holdings, Inc. profitable?
No. Senseonics Holdings, Inc. is loss-making, with a net margin of -204.17% over the trailing twelve months.
What is the analyst price target for SENS?
Wall Street analysts rate SENS Buy, with an average price target of $13.00, 24.8% above the current price.
What sector is Senseonics Holdings, Inc. in?
Senseonics Holdings, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Senseonics Holdings, Inc.?
Timothy T. Goodnow is the chief executive of Senseonics Holdings, Inc., which employs 130 people.
Where can I track SENS in real time?
QFI Terminal shows SENS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SENS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SENS in Terminal See plans